Concourse Financial Group Securities’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
– Sell
-33
Closed -$298 – 2475
2021
Q3
$0 Hold
33
– – ﹤0.01% 2484
2021
Q2
$0 Hold
33
– – ﹤0.01% 2441
2021
Q1
$0 Sell
33
-1,100
-97% -$12.6K ﹤0.01% 2421
2020
Q4
$11K Sell
1,133
-481
-30% -$4.61K ﹤0.01% 1669
2020
Q3
$15K Buy
1,614
+481
+42% +$5.09K ﹤0.01% 1456
2020
Q2
$14K Buy
1,133
+1,100
+3,333% +$12.4K ﹤0.01% 1412
2020
Q1
$0 Hold
33
– – ﹤0.01% 2314
2019
Q4
$0 Buy
+33
New +$295 ﹤0.01% 2134
2019
Q3
– Sell
-913
Closed -$7K – 2124
2019
Q2
$8K Sell
913
-1,342
-60% -$16.2K ﹤0.01% 1578
2019
Q1
$34K Buy
2,255
+1,080
+92% +$19K ﹤0.01% 1033
2018
Q4
$18K Buy
1,175
+33
+3% +$677 ﹤0.01% 1210
2018
Q3
$25K Buy
+1,142
New +$26.5K 0.01% 797

Other funds holding TEVA

Concourse Financial Group Securities's TEVA Position: Q4 2021 in Review

Concourse Financial Group Securities sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2021, closing a stake of 33 shares — an estimated $298 sold.

Concourse Financial Group Securities first reported a position in TEVA in Q3 2018 and held it in 12 quarters. The position peaked at $34K in Q1 2019. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

  • Concourse Financial Group Securities reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2021 after selling out during the quarter.
  • Concourse Financial Group Securities sold 33 Teva Pharmaceutical Industries Limited shares in Q4 2021, an estimated $298.
  • Concourse Financial Group Securities first reported a position in Teva Pharmaceutical Industries Limited in Q3 2018 and held it in 12 quarters.
  • Concourse Financial Group Securities's Teva Pharmaceutical Industries Limited position peaked at $34K in Q1 2019.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2021.

Based on Concourse Financial Group Securities's 13F filing for Q4 2021, filed 7 Feb 2022.